Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A team of medical research and statistical modelling experts at Oxford University and the Alan Turing Institute have conducted a joint analysis to assess the impact of the NHS COVID-19 contact tracing app.

Phone screen showing the app in use

The research suggests the app stopped between 200,000 and 900,000 infections between 1st October and 31st December 2020, when 1.9 million people were infected with coronavirus in England and Wales.

Christophe Fraser, Professor of Pathogen Dynamics at Oxford University’s Big Data Institute, Nuffield Department of Medicine, explains: 'We used two separate approaches to analyse the impact of the more than 1.5 million notifications sent by the app in 2020, and both showed that between 200,000 and 900,000 infections have been averted. The impact of the app could be increased if more people use it. For each 1% increase in users we estimate the number of cases will drop by between 0.8% and 2.3%.'

The report shows the app was downloaded onto over 21 million phones, out of 33.7 million eligible people with compatible smartphones living in England and Wales. In 2020, the app sent out an average of 4.4 quarantine notifications for each user who shared their positive test result though the app. Most alerts went out in the second half of December when cases were rising rapidly across the UK due to the new B117 variant.

Read the full story on the University of Oxford website.

The story is also featured in the Fraser Group Coronavirus blog.

Similar stories

Oxford joins forces with 11 universities to launch social impact investment fund

The University of Oxford has joined forces with 11 leading universities to create Impact 12, an impact investment fund to support mission-led university ventures.

Potential for radiotherapy and VTP multimodality therapy for prostate cancer

A recent collaborative study from the University of Oxford has investigated the potential benefit of a combined therapy approach to prostate cancer treatment, using radiotherapy and vascular targeted photodynamic therapy (VTP), which could lead to first-in-man early phase clinical trials.

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.

First trimester placental scan - Artificial Intelligence in Health and Care Award

A first trimester 3D placental ultrasound scan which can predict fetal growth restriction and pre-eclampsia, could become part of a woman's routine care thanks to a new Artificial Intelligence in Health and Care Award.

Impaired antibody response to COVID-19 vaccination in patients with myeloid blood cancers

Oxford researchers have found that antibody responses to the first doses of COVID-19 vaccine in people with chronic myeloid blood cancers are not as strong as those among the general population.

Oxford University and partners win government funding to evaluate Paige Prostate Cancer Detection System

A prostate cancer detection software system to help pathologists quickly identify suspicious areas of tissue, developed by Paige, will be investigated in a multicentre clinical study led by Oxford University as part of a successful NHSx Artificial Intelligence Health and Care Award application.